Table 6.

Adjusted hazard ratios for nonrelapse mortality and overall survival as stratified by augmented comorbidity/age index comparing alternative graft sources

	HR (95% CI)	p-value	Adjusted* HR (95% CI)	Adjusted* p-value
Nonrelapse mortality with augmented comorbidity/age score <4
Antigen mismatched	1.0		1.0
Cord blood	0.87 (0.55–1.38)	0.56	0.98 (0.59–1.62)	0.94
Haploidentical	1.42 (0.82–2.47)	0.21	1.24 (0.58–2.63)	0.58
Nonrelapse mortality with augmented comorbidity/age score ≥4
Antigen mismatched	1.0		1.0
Cord blood	1.06 (0.75–1.48)	0.75	1.40 (0.88–2.24)	0.16
Haploidentical	1.18 (0.78–1.77)	0.43	1.48 (0.82–2.66)	0.19
Overall Survival with augmented comorbidity/age score <4
Antigen mismatched	1.0		1.0
Cord blood	0.73 (0.52–1.04)	0.08	0.84 (0.58–1.23)	0.37
Haploidentical	0.96 (0.61–1.51)	0.86	0.99 (0.53–1.86)	0.99
Overall survival with augmented comorbidity/age score ≥4
Antigen mismatched	1.0		1.0
Cord blood	0.87 (0.65–1.17)	0.36	0.94 (0.64–1.36)	0.73
Haploidentical	1.16 (0.83–1.63)	0.38	1.20 (0.76–1.91)	0.43

^*Adjusted for conditioning (myeloablative, reduced-intensity, or nonmyeloablative), age (<50, ≥50), cytomegalovirus serostatus (+, −), disease risk (low, high), and Karnofsky Performance Status score (≤80, >80)